Skip to content

Replimune Group REPL Net Investment in Lease

Net Investment in Lease at other companies

Inhibrx Biosciences, Inc. logo
Inhibrx Biosciences, Inc.INBX
Immunome logo
ImmunomeIMNM
CG Oncology logo
CG OncologyCGON
Erasca, Inc. logo
Erasca, Inc.ERAS
Relay Therapeutics, Inc. logo
Relay Therapeutics, Inc.RLAY
IDEAYA Biosciences, Inc. logo
IDEAYA Biosciences, Inc.IDYA

Other financials

Income statement

See full
Operating income-$71.9M-8.9%
Net income-$70.9M-6.9%
EPS (diluted)-$0.77+2.5%

Balance sheet

See full
Cash & equivalents$124.7M-28.3%
Total debt$79.2M+0.5%
Total equity$210.5M-56.4%
Total assets$333.6M-44.7%

Cash flow

See full
Operating cash flow-$66.0M-30.1%
CapEx$135.0K-92.5%
Free cash flow-$66.1M-25.9%

Valuation

See full
Market cap$930.59M+30.2%
Enterprise value$885.15M+30.0%

Returns & leverage

See full
Return on equity-90.9%+362pp
Debt / equity0.4×+0.2×
Current ratio5.6×-5.8×

Where this comes from

Reported directly by Replimune Group in its filing.

Tagged under the XBRL concept us-gaap:OperatingLeaseRightOfUseAsset.

The official record: Replimune Group’s 10-Q, filed February 3, 2026, on SEC EDGAR. View the filing →

Ask your AI about Replimune Group's net investment in lease.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Replimune Group's net investment in lease?
Replimune Group (REPL) reported net investment in lease of $3.5M in Q4 2025.
How has Replimune Group's net investment in lease changed year-over-year?
Replimune Group's net investment in lease decreased by 15.1% year-over-year, from $4.12M to $3.5M.
What is the long-term trend for Replimune Group's net investment in lease?
Over 4 years (2021 to 2025), Replimune Group's net investment in lease has grown at a -8.7% compound annual growth rate (CAGR), from $5.75M to $4M.